by ASTCT Talks
In this episode of ASTCT Talks, host Terri Lynn Shigle, PharmD, BCOP, Clinical Pharmacy Specialist in the Stem Cell Transplantation and Cellular Therapy Department at The University of Texas MD...
by Alex Kadhim
A recent study published in The Lancet Haematology has demonstrated that patients with aggressive B-cell lymphomas experience a substantial burden of symptoms shortly after CAR T-cell infusion,...
by Alex Kadhim
Researchers at the University of Pennsylvania have found that CAR T-cell therapy response in recurrent glioblastoma (GBM) is affected by divergent remodeling of the immune system.
by ASTCT Talks
In this episode of ASTCT Talks, host Daniel Olson, MD, of the University of Chicago, is joined by Stephanie Goff, MD, of the National Cancer Institute (NCI), and Allison Betof, MD, PhD, of...
by Blood Advances
Researchers say promising Phase I evidence justifies advanced clinical trials to investigate the use of arlocabtagene autoleucel (arlo-cel) in patients with heavily pretreated relapsed or...
by Blood Advances
Researchers report that further study is warranted after baricitinib achieved significant durable response in a small sample of patients with refractory severe chronic graft-versus-host disease...